Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MedAdvisor Limited ( (AU:MDR) ) has shared an update.
MedAdvisor Limited announced an amendment to their Appendix 4C for the quarter ended 30 September 2025, correcting errors in financial disclosures related to proceeds from the disposal of businesses and cash balances. The company clarified that the cash balance at the end of the period remains unchanged at $12.995 million and reaffirmed its commitment to continuous disclosure best practices.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Solutions (ASX: MDR) is a leader in pharmacy-driven patient engagement solutions, providing personalized experiences to simplify the medication journey. Utilizing THRiV, a cloud-based, AI-enabled platform, the company enhances pharmacy workflows and patient engagement, working with over 25,000 pharmacies across the US, reaching over two-thirds of the population.
Average Trading Volume: 1,456,339
Technical Sentiment Signal: Sell
Current Market Cap: A$12.69M
For detailed information about MDR stock, go to TipRanks’ Stock Analysis page.